
The Last Word on JAK Inhibitor Safety and 1133 Study (1.28.2022)
Rheumnow Podcast
00:00
Do Boosters Work in Immunocompromised Patients?
There were more mace events, major adverse cardovasker events etopa group versus the t and f and hipiter group. This was beyond the upper limits of non inferiority, and that's why it gets a higher label. And we're going to end with a discussion of the a oral surveillance study, the 11 33 study, done by feiser in high risk r a patience,. Just published this week, new england journal. If you haven't heard about this study, oral surveillance, or also called 11 33, you must be living under a rock.
Transcript
Play full episode